Dirk Schadendorf

6 ta ish

University of Duisburg-Essen

1. Improved Survival with Ipilimumab in Patients with Metastatic Melanoma

   F. Stephen Hodi, Steven O’Day, David F. McDermott +26

   MaqolaOAOchiq kirish201010 iqtibos

   ABIABI:AkademIndex/2026.other.121325

2. Combined Nivolumab and Ipilimumab or Monotherapy in Untreated Melanoma

   James Larkin, Vanna Chiarion‐Sileni, René González +28

   MaqolaOAOchiq kirish20153 iqtibos

   ABIABI:AkademIndex/2026.other.170114

3. Skin Cancer Classification Using Convolutional Neural Networks: Systematic Review

   Titus J. Brinker, Achim Hekler, Jochen Utikal +7

   Sharh maqolaOAOchiq kirish20182 iqtibos

   ABIABI:AkademIndex/2026.other.019050

4. Overall Survival with Combined Nivolumab and Ipilimumab in Advanced Melanoma

   Jedd D. Wolchok, Vanna Chiarion‐Sileni, René González +30

   MaqolaOAOchiq kirish20172 iqtibos

   ABIABI:AkademIndex/2026.other.082822

5. Clonal neoantigens elicit T cell immunoreactivity and sensitivity to immune checkpoint blockade

   Nicholas McGranahan, Andrew J.S. Furness, Rachel Rosenthal +33

   MaqolaOAOchiq kirish20162 iqtibos

   ABIABI:AkademIndex/2026.other.102835

6. Nivolumab in Previously Untreated Melanoma without <i>BRAF</i> Mutation

   Caroline Robert, Georgina V. Long, Benjamin Brady +25

   MaqolaOAOchiq kirish20142 iqtibos

   ABIABI:AkademIndex/2026.other.241891